A detailed history of Fin Trust Capital Advisors, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 14 shares of VIR stock, worth $103. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 14 -0.0%
Holding current value
$103
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 24, 2023

SELL
$9.14 - $24.62 $22,850 - $61,550
-2,500 Reduced 99.44%
14 $0
Q3 2022

Oct 20, 2022

BUY
$18.26 - $31.1 $45,631 - $77,718
2,499 Added 16660.0%
2,514 $54,000
Q2 2022

Jul 26, 2022

SELL
$19.08 - $26.7 $38,160 - $53,400
-2,000 Reduced 99.26%
15 $0
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $62,404 - $108,870
2,015 New
2,015 $84,000
Q3 2021

Nov 16, 2021

SELL
$34.9 - $54.54 $17,450 - $27,270
-500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$26.34 - $83.07 $13,170 - $41,535
500 New
500 $26,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $979M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Fin Trust Capital Advisors, LLC Portfolio

Follow Fin Trust Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.